Patient Information Leaflet for COVID

Updated 13 July 2022

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-valneva/patient-information-leaflet-for-covid-19-vaccine-valneva

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects your child may get. See the end of section 4 for how to report side effects.

COVID-19 Vaccine Valneva is a vaccine used to prevent COVID-19 caused by SARS-CoV-2.

COVID-19 Vaccine Valneva is given to adults aged between 18 and 50 years.

The vaccine causes the immune system (the body’s natural defences) to produce antibodies and blood cells that works against the virus so giving protection against COVID-19.

None of the ingredients in this vaccine can cause COVID-19.

Tell your doctor, pharmacist or nurse before you are given COVID-19 Vaccine Valneva if:

Two doses of COVID-19 Vaccine Valneva are necessary to start protecting you. As with any vaccine, even the 2-dose vaccination course may not fully protect all those who receive it and it is not known how long you will be protected. No data are currently available in individuals with a weakened immune system or who are taking chronic treatment that suppresses or prevents immune responses.

COVID-19 Vaccine Valneva is not recommended for children and adolescents aged below 18 years. Currently there is not enough information available on the use of COVID-19 Vaccine Valneva in children and adolescents younger than 18 years of age.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines or other vaccines.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you receive this vaccine.

Some of the side effects of COVID-19 Vaccine Valneva listed in section 4 may temporarily affect your ability to drive and use machines. Do not drive or use machines if you are feeling unwell after vaccination. Wait until any effects of the vaccine have worn off before you drive or use machines.

This vaccine contains potassium, less than 1 mmol (39 mg) per 0.5 mL dose, i.e. essentially ‘potassium-free’.

This vaccine contains less than 1 mmol sodium (23 mg) per 0.5 mL dose, that is to say essentially ‘sodium-free’.

COVID-19 Vaccine Valneva is given as an injection of 0.5 mL into a muscle of your upper arm.

You will receive 2 injections of the same vaccine, given at least 28 days apart to complete the vaccination course.

If you miss an appointment for your second injection of COVID-19 Vaccine Valneva, it is important that you return for your second injection as you are not protected against COVID-19.

If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur with COVID-19 Vaccine Valneva:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

If you are concerned about a side-effect it can be reported directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. When completing a report please include the vaccine brand and batch/Lot number if available. By reporting side effects you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and label after “EXP”. The expiry date refers to the last day of that month.

Information about storage, expiry, and use and handling are described in the section intended for healthcare professionals at the end of the package leaflet.

The active substance is a highly purified whole virus SARS-CoV-2 antigen¹, inactivated² and adjuvanted with CpG 1018³ in combination with aluminium hydroxide⁴.

One multi-dose vial contains 10 single doses of 0.5 mL.

One dose (0.5 mL) contains no less than 25 Antigen Units (AU) of inactivated SARS-CoV-2.

¹ Produced on Vero cells

² Inactivated with beta-propiolactone

³ 1 mg CpG 1018 (cytosine phospho-guanine) adjuvant/0.5 mL dose

⁴ Adsorbed on aluminium hydroxide (0.5 mg Al3+)/0.5 mL dose

The other ingredients are: sodium chloride, sodium phosphate dibasic anhydrous, potassium phosphate mono anhydrous, potassium chloride, water for injections and recombinant human albumin (rHA) containing sodium, octanoate, and polysorbate 80.

White to off-white suspension for injection (injection) in a glass multi-dose vial closed with rubberstopper and a flip-off plastic cap with aluminium seal.

Pack size: 10 multi-dose vials

Valneva Austria GmbHCampus Vienna Biocenter 31030 ViennaAustria

Valneva Scotland LimitedOakbank Park RoadLivingston EH53 OTGScotland, UK

For any information about this medicine, please contact the Marketing Authorisation Holder by thefollowing email-address: [email protected]

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. Thismeans that further evidence on this medicinal product is awaited. New information on this medicinalproduct will be reviewed at least every year and this leaflet will be updated as necessary.